Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis

人急性白血病细胞E-选择素配体分析及其在白血病发生中的生物学作用

基本信息

项目摘要

ABSTRACT: The tetrasaccharide known as “sialylated Lewis X” (sLeX; CD15s) is the prototypical binding determinant for E- selectin (CD62E), a Ca++-dependent lectin expressed on vascular endothelial cells. Through investigations described herein, we aim to unveil how this structure, and the underlying glycosyltransferases (GTs) controlling its biosynthesis, mediate(s) human leukemogenesis. The sLeX motif can be presented on cell surfaces on protein (i.e., glycoprotein) and/or lipid (i.e., glycolipid) scaffolds, and these glycoconjugates (known as “E-selectin ligands”) program shear-resistant adhesion to endothelial cells. E-selectin is typically not displayed on resting vascular endothelial cells, and its expression is induced by inflammatory cytokines such as TNF and IL-1. How- ever, conspicuously, E-selectin is constitutively expressed on bone marrow (BM) sinusoidal vessels where it is known to play a key role in mediating migration of circulating cells to BM, a process critical to blood cell recovery following hematopoietic stem cell transplantation (HSCT). Beyond its role in recruiting hematopoietic stem/pro- genitor cells (HSPCs) to BM, it is well-known that E-selectin expression on marrow microvessels serves a fun- damental role in creation of hematopoietic growth-promoting microenvironments, collectively known as “vascular niches”. Studies from our laboratory have shown that human HSPCs express a variety of E-selectin ligands, and we have also observed that leukemic blasts characteristically express E-selectin ligands. We hypothesize that engagement of E-selectin ligands on human acute leukemia cells programs efficient BM metastasis and also enables niche lodgment, serving to displace resident HSPCs from their proper growth microenvironment and thereby promoting leukemic cell proliferation. In this proposal, using E-selectin binding assays under both static and fluid shear conditions, together with complementary techniques in flow cytometry and western blotting, we will analyze the E-selectin binding activity of leukemia cells isolated from blood and BM of patients with acute leukemias. We will identify the pertinent sLeX-bearing glycoconjugates among the different types of human leu- kemia cells, measure the ability of such glycoconjugates to engage E-selectin, and determine how expression of Golgi GTs shape creation of sLeX modifications among the different E-selectin ligands. This information will be integrated with various biochemical approaches including metabolic inhibition of glycosylation and cell surface glycoengineering to custom-modify sLeX display to assess the extent to which sLeX presentation on a specific protein and/or lipid scaffold licenses E-selectin binding among blasts from various subtypes of human acute leukemias, and the impact of the relevant E-selectin receptor/ligand interaction(s) in leukemia cell biology. The results of proposed studies will be key to elucidating the glycobiology of leukemogenesis, and should also pro- vide fundamental insights for establishing novel strategies to treat acute leukemias by selectively interrupting sLeX expression and/or E-selectin ligand-mediated processes, and for potential therapy/prognosis stratification schemas based on sLeX levels and/or the expression of distinct E-selectin ligands on acute leukemia cells. Relevance: Acute leukemia arises because abnormal white cell precursors proliferate within special growth zones within the bone marrow. There is increasing evidence that these growth zones are created by the display of particular sugar molecules on the surface of blood cells that act like Velcro to anchor the cells to marrow vessels. This research project will study these sugar structures and how they are made, with anticipation that information obtained will pave the way for more effective therapies for acute leukemias and may also allow for more precise identification of patients needing more intensive treatment and/or closer monitoring.
摘要: 被称为“唾液酸化的Lewis X”(SLeX;CD15s)的四糖是E-的典型结合决定簇。 选择素(CD62E)是一种表达于血管内皮细胞的钙依赖凝集素。通过调查 在这里,我们的目标是揭示这种结构和潜在的糖基转移酶(GTS)是如何控制的 其生物合成,介导(S)人白血病的发生。SLeX基序可以呈现在细胞表面的 蛋白质(即,糖蛋白)和/或脂类(即,糖脂)支架,以及这些糖共轭化合物(称为“E-选择素 配体“)程序与内皮细胞的抗剪切粘附性。休息时通常不显示E-选择素 血管内皮细胞,其表达由炎性细胞因子如肿瘤坏死因子和白介素1诱导。怎么- 值得注意的是,E-选择素在其所在的骨髓(BM)窦血管上有结构性地表达 已知在调节循环细胞向骨髓迁移的过程中发挥关键作用,这是血细胞恢复的关键过程 在造血干细胞移植(HSCT)后。除了在招募造血干细胞/前体方面的作用外- 骨髓微血管上E-选择素的表达在骨髓细胞对骨髓间充质干细胞(HSPC)的分化中起重要作用。 在创造促进造血生长的微环境中的基础作用,统称为“血管 利基市场“。我们实验室的研究表明,人类HSPC表达多种E-选择素配体,并且 我们还观察到白血病细胞特有地表达E-选择素配体。我们假设 E-选择素配体在人急性白血病细胞上的结合可促进有效的骨髓转移 支持利基寄宿,使居住的HSPC脱离其适当的生长微环境,并 从而促进白血病细胞增殖。在本方案中,使用E-选择素结合分析在两种静态条件下 和流体剪切条件,再加上流式细胞术和免疫印迹的补充技术,我们 将分析急性白血病患者血液和骨髓中分离的白血病细胞的E-选择素结合活性 白血病。我们将在不同类型的人类白血病中鉴定相关的含SLeX的糖偶联物。 白血病细胞,测量这种糖结合物结合E-选择素的能力,并确定如何表达 高尔基GTS的形状在不同的E-选择素配体之间产生SLeX修饰。此信息将 与各种生化方法相结合,包括代谢抑制糖基化和细胞表面 自定义修改SLeX显示以评估SLeX在特定环境中的演示程度 蛋白质和/或脂质支架允许E-选择素在人类急性白血病不同亚型的原始细胞中结合 白血病,以及相关的E-选择素受体/配体相互作用(S)在白血病细胞生物学中的影响。这个 拟议的研究结果将是阐明白血病发生的糖生物学的关键,也应该有利于 通过选择性阻断来建立治疗急性白血病的新策略的基本见解 SLeX表达和/或E-选择素配体介导的过程和潜在治疗/预后分层 基于SLeX水平和/或急性白血病细胞上不同E-选择素配体表达的模式。 相关性:急性白血病的发生是因为异常的白细胞前体在特殊的生长过程中增殖 骨髓内的区域。越来越多的证据表明,这些生长带是由显示器造成的 血细胞表面的特殊糖分子,它们像尼龙搭扣一样将细胞固定在骨髓上 船只。这项研究项目将研究这些糖的结构以及它们是如何形成的,预计 所获得的信息将为更有效地治疗急性白血病铺平道路,并可能允许 更准确地识别需要更密集治疗和/或更密切监测的患者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Constantine S. Mitsiades其他文献

The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges
1q 异常在多发性骨髓瘤中的作用:基因组学见解、临床意义和治疗挑战
  • DOI:
    10.1053/j.seminhematol.2024.10.001
  • 发表时间:
    2025-02-01
  • 期刊:
  • 影响因子:
    4.100
  • 作者:
    Zachary M. Avigan;Constantine S. Mitsiades;Alessandro Laganà
  • 通讯作者:
    Alessandro Laganà
AUTOSOMAL DOMINANT INHERITANCE OF SCHMID'S METAPHYSEAL CHONDRODYSPLASIA : DESCRIPTION OF A NEW FAMILY, AND INVESTIGATION OF THE COL10A1 GENE. 874
施密特干骺端软骨发育不良的常染色体显性遗传:一个新家族的描述及 COL10A1 基因的研究。874
  • DOI:
    10.1203/00006450-199604001-00896
  • 发表时间:
    1996-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Constantine A. Stratakis;Alessandra Vottero;Constantine S. Mitsiades;Val Abbassi
  • 通讯作者:
    Val Abbassi
Gene Editing and Multi-Omics Reveal Novel Metabolic Vulnerabilities in t(4;14)-Associated Multiple Myeloma
  • DOI:
    10.1182/blood-2022-169256
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Amin Sobh;Charlotte L Kaestner;Alberto Riva;Karthik Vasan;Alisha Patel;Greeshma Surapaneni;Janai Poullard;Elena Encinas;Richard Lynn Bennett;Constantine S. Mitsiades;Lawrence H. Boise;Navdeep S. Chandel;Jonathan D. Licht
  • 通讯作者:
    Jonathan D. Licht
The role of tumour–stromal interactions in modifying drug response: challenges and opportunities
肿瘤-基质相互作用在改变药物反应中的作用:挑战与机遇
  • DOI:
    10.1038/nrd3870
  • 发表时间:
    2013-03-01
  • 期刊:
  • 影响因子:
    101.800
  • 作者:
    Douglas W. McMillin;Joseph M. Negri;Constantine S. Mitsiades
  • 通讯作者:
    Constantine S. Mitsiades
Systematic Functional Characterization for Loss of Function Events Cooperating with TP53 Loss in High-Risk 17p13(del) Multiple Myeloma
  • DOI:
    10.1182/blood-2022-159316
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Phaik Ju Teoh;Ricardo De Matos Simoes;Tae-Hoon Chung;Mick Lee;Olga Dashevsky;Shizuka Yamano;Roger Foo;Wee Joo Chng;Constantine S. Mitsiades
  • 通讯作者:
    Constantine S. Mitsiades

Constantine S. Mitsiades的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Constantine S. Mitsiades', 18)}}的其他基金

Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies
血液系统恶性肿瘤中持续治疗残留肿瘤细胞的自然杀伤细胞耐药机制
  • 批准号:
    10564354
  • 财政年份:
    2023
  • 资助金额:
    $ 42.96万
  • 项目类别:
Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis
人急性白血病细胞E-选择素配体分析及其在白血病发生中的生物学作用
  • 批准号:
    10441418
  • 财政年份:
    2019
  • 资助金额:
    $ 42.96万
  • 项目类别:
Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis
人急性白血病细胞E-选择素配体分析及其在白血病发生中的生物学作用
  • 批准号:
    10384552
  • 财政年份:
    2019
  • 资助金额:
    $ 42.96万
  • 项目类别:
Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis
人急性白血病细胞E-选择素配体分析及其在白血病发生中的生物学作用
  • 批准号:
    10646189
  • 财政年份:
    2019
  • 资助金额:
    $ 42.96万
  • 项目类别:
Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis
人急性白血病细胞E-选择素配体分析及其在白血病发生中的生物学作用
  • 批准号:
    9979808
  • 财政年份:
    2019
  • 资助金额:
    $ 42.96万
  • 项目类别:

相似海外基金

Targeting Menin in Acute Leukemia with Upregulated HOX Genes
通过上调 HOX 基因靶向急性白血病中的 Menin
  • 批准号:
    10655162
  • 财政年份:
    2023
  • 资助金额:
    $ 42.96万
  • 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
  • 批准号:
    10839678
  • 财政年份:
    2023
  • 资助金额:
    $ 42.96万
  • 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
  • 批准号:
    10651543
  • 财政年份:
    2023
  • 资助金额:
    $ 42.96万
  • 项目类别:
Experimental and preclinical modeling of NUP98-rearranged acute leukemia
NUP98重排急性白血病的实验和临床前模型
  • 批准号:
    10829603
  • 财政年份:
    2023
  • 资助金额:
    $ 42.96万
  • 项目类别:
A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia
预测儿童急性白血病甲氨蝶呤神经毒性的系统流行病学方法
  • 批准号:
    10655716
  • 财政年份:
    2023
  • 资助金额:
    $ 42.96万
  • 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
  • 批准号:
    10435886
  • 财政年份:
    2022
  • 资助金额:
    $ 42.96万
  • 项目类别:
mRNA stability and its impact on hematopoiesis and acute leukemia
mRNA稳定性及其对造血和急性白血病的影响
  • 批准号:
    10339742
  • 财政年份:
    2022
  • 资助金额:
    $ 42.96万
  • 项目类别:
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
通过多层次干预使急性白血病临床试验招募多样化
  • 批准号:
    10505579
  • 财政年份:
    2022
  • 资助金额:
    $ 42.96万
  • 项目类别:
Clonal dynamics and chemoresistance mechanisms of minimal residual disease in acute leukemia
急性白血病微小残留病的克隆动力学和化疗耐药机制
  • 批准号:
    10351765
  • 财政年份:
    2022
  • 资助金额:
    $ 42.96万
  • 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
  • 批准号:
    10576955
  • 财政年份:
    2022
  • 资助金额:
    $ 42.96万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了